Cefazolin

Evidence Level: L5

Predicted Indications: 8

Cefazolin

Pharmacist Assessment Report

Cefazolin: first-generation cephalosporin (bacterial cell wall synthesis inhibitor) → infectious otitis media

One-Sentence Summary

Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis. The TxGNN model predicts it may be useful for infectious otitis media, but no clinical trials and only 2 publications were retrieved for this disease, and neither directly tests cefazolin as a treatment for it. The prediction is currently supported mainly by the model score and a plausible antibacterial mechanism.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	infectious otitis media
TxGNN Prediction Score	0.9944
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Cefazolin belongs to the first-generation cephalosporins, which bind penicillin-binding proteins and inhibit bacterial cell wall synthesis. It is active against Gram-positive organisms such as streptococci and staphylococci, which can cause otitis media.

There are important limits. Cefazolin has weak activity against Haemophilus influenzae and Moraxella catarrhalis, two of the other major otitis media pathogens. Established agents are also available for this condition. The mechanism is therefore plausible but only partly matched to the usual pathogens.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39567876	2025	Case report/series	Annals of Otology, Rhinology & Laryngology	Ceftazidime-cefazolin empiric therapy in paediatric Gradenigo syndrome, a rare complication of acute otitis media; case-level observation only
3742953	1986	Review	Clinical Pharmacy	Management of Stevens-Johnson syndrome; otitis media appears only as a background illness in the case, so it is not relevant to this indication

Neither publication studies cefazolin as a treatment of infectious otitis media itself. Neither therefore meets the standard for direct evidence, and the evidence level is L5.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
12115P	Cephazolin Viatris	Powder for injection 2 g (as sodium)	Not recorded in the local data

The product is a single-ingredient injectable and its licence is valid.

Safety Considerations

Drug Interactions: Interaction screening returned 100 entries. Moderate-level interactions include the aminoglycosides kanamycin, neomycin and streptomycin, and picosulfuric acid. Other entries, such as amphotericin B, are of unknown severity.

For warnings and contraindications, please refer to the TGA-approved Product Information (PI).

Conclusion and Next Steps

Decision: Hold

Rationale: The score is high (0.9944), but no trials exist and the only retrieved studies do not directly test cefazolin in this disease. The spectrum gap against H. influenzae and M. catarrhalis, together with existing standard therapy, argues against prioritising this indication now.

To proceed, the following is needed:

Direct clinical data for cefazolin in infectious otitis media, such as comparative studies against standard therapy
Local susceptibility data for the main otitis media pathogens
Detailed mechanism of action data
Review of the TGA Product Information for warnings and contraindications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.